ADMA BIOLOGICS, INC. (NASDAQ:ADMA) Files An 8-K Other Events

ADMA BIOLOGICS, INC. (NASDAQ:ADMA) Files An 8-K Other Events
Item 8.01

On October 17, 2019, ADMA Biologics, Inc. issued a press release entitled “ADMA Biologics Announces Publication of an Article Describing the Manufacturing Process Optimization for its Commercial Products BIVIGAM® and ASCENIV™ in the Peer Reviewed Journal Immunotherapy.” The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

(d) Exhibits

99.1 Press release dated October 17, 2019, entitled “ADMA Biologics Announces Publication of an Article Describing the Manufacturing Process Optimization for its Commercial Products BIVIGAM® and ASCENIV™ in the Peer Reviewed Journal Immunotherapy.”


ADMA BIOLOGICS, INC. Exhibit
EX-99.1 2 e619124_ex99-1.htm   Exhibit 99.1       ADMA Biologics Announces Publication of an Article Describing the Manufacturing Process Optimization for its Commercial Products BIVIGAM® and ASCENIV™ in the Peer Reviewed Journal Immunotherapy   RAMSEY,…
To view the full exhibit click here

Story continues below

About ADMA BIOLOGICS, INC. (NASDAQ:ADMA)

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.

An ad to help with our costs